October 28, 2019
ARLINGTON, Va. — In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.
“We are encouraged the DEA continues to address its quota setting for opioids amidst this public health crisis. As the primary regulator of the supply chain, the DEA has the ability to control the supply of opioid in the marketplace and limit excess quantities of medications that might be vulnerable to diversion and illicit use.
“As an industry, distributors have long advocated for the DEA to gradually reduce the production quotas for opioid medicines by working closely with providers and patient groups to assess and determine current needs and revisit annual production quotas accordingly.
“HDA and our distributor members continue to support practical solutions that will improve monitoring and response among the DEA and the supply chain while advancing meaningful reforms to end the prescription opioid abuse epidemic.”
For more information on the DEA’s role in the pharmaceutical supply chain, click here.
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.